OncoMatch/Clinical Trials/NCT06207799
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Is NCT06207799 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for multiple myeloma.
Treatment: Elranatamab · Lenalidomide · Plerixafor · Melphalan · Busulfan · G-CSF — To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM. An ASTC is a type of transplant in which a person's own stem cells are collected, preserved, and returned to them.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: TP53 17p13 deletion
Presence of a high-risk chromosomal abnormality (HRCA) including: 17p13 deletion
Required: IGH t(4;14)
Presence of a high-risk chromosomal abnormality (HRCA) including: t(4;14)
Required: IGH t(14;16)
Presence of a high-risk chromosomal abnormality (HRCA) including: t(14;16)
Required: IGH t(14;20)
Presence of a high-risk chromosomal abnormality (HRCA) including: t(14;20)
Required: CKS1B gain or amplification 1q
Presence of a high-risk chromosomal abnormality (HRCA) including: Gain or amplification 1q by FISH
Demographics
Prior therapy
Must have received: induction therapy
Participants with disease response PR to induction therapy
Cannot have received: systemic anti-myeloma therapy
Exception: within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug
Participant must not have used an investigational drug or approved systemic anti-myeloma therapy (including systemic steroids) within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug.
Lab requirements
Kidney function
Estimated creatinine clearance 40 mL/min
Liver function
total bilirubin 1.5X ULN; ALT 2.5 X ULN
Adequate liver function (total bilirubin 1.5X ULN; ALT 2.5 X ULN) Estimated creatinine clearance 40 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06207799 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anti-myeloma therapy disqualifies patients from enrollment.
Does this trial require TP53?
Yes, TP53 17p13 deletion is a required biomarker for enrollment.
Does this trial require IGH?
Yes, IGH t(4;14) is a required biomarker for enrollment.
Does this trial require IGH?
Yes, IGH t(14;16) is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages